MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
Overall MYGN gets a fundamental rating of 3 out of 10. We evaluated MYGN against 577 industry peers in the Biotechnology industry. Both the profitability and financial health of MYGN have multiple concerns. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MYGN has reported negative net income.
MYGN had a negative operating cash flow in the past year.
MYGN had negative earnings in 4 of the past 5 years.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
MYGN's Return On Assets of -21.13% is fine compared to the rest of the industry. MYGN outperforms 78.75% of its industry peers.
Looking at the Return On Equity, with a value of -30.87%, MYGN is in the better half of the industry, outperforming 79.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -30.87% | ||
| ROIC | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of MYGN (68.79%) is better than 83.45% of its industry peers.
MYGN's Gross Margin has declined in the last couple of years.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYGN has more shares outstanding
The number of shares outstanding for MYGN has been increased compared to 5 years ago.
MYGN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.01 indicates that MYGN is not in any danger for bankruptcy at the moment.
The Altman-Z score of MYGN (4.01) is better than 76.31% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that MYGN is not too dependend on debt financing.
MYGN's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. MYGN is outperformed by 61.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.01 |
ROIC/WACCN/A
WACC10.7%
2.3 Liquidity
A Current Ratio of 1.99 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a worse Current ratio (1.99) than 77.00% of its industry peers.
MYGN has a Quick Ratio of 1.82. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MYGN (1.82) is worse than 77.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 83.33% over the past year.
Looking at the last year, MYGN shows a quite strong growth in Revenue. The Revenue has grown by 11.44% in the last year.
The Revenue has been growing slightly by 0.25% on average over the past years.
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
Revenue 1Y (TTM)11.44%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.59%
3.2 Future
MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.08% yearly.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 7.14% on average per year.
EPS Next Y111.57%
EPS Next 2Y66.94%
EPS Next 3Y52.4%
EPS Next 5Y33.08%
Revenue Next Year10.72%
Revenue Next 2Y9.15%
Revenue Next 3Y8.42%
Revenue Next 5Y7.14%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MYGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 125.50, which means the current valuation is very expensive for MYGN.
MYGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 91.46% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MYGN to the average of the S&P500 Index (20.59), we can say MYGN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 125.5 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
MYGN's earnings are expected to grow with 52.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.94%
EPS Next 3Y52.4%
5. Dividend
5.1 Amount
No dividends for MYGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYRIAD GENETICS INC
NASDAQ:MYGN (7/26/2024, 3:46:34 PM)
After market: 27.65 0 (0%)27.65
-0.2 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.50B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 125.5 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -30.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.79% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y111.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.44%
Revenue growth 3Y5.66%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y